Polymeric particles for the controlled release of human amylin

Colloids and Surfaces B: Biointerfaces

Volumn 94, Issue , 2012, Pages 101-106

  Guerreiro, Luiz Henrique ^a   Da Silva, Daniel ^a   Ricci Junior, Eduardo ^a   Girard Dias, Wendell ^a   Mascarenhas, Camile Moreira ^a   Sola Penna, Mauro ^a   Miranda, Kildare ^a   Limaa, Luís Maurício T R ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Amylin; Diabetes; Glycemia; Islet associated polypeptide; Nanoparticles; Poly e open caprolactone

Indexed keywords

AMYLIN; CAPROLACTONE; CONTROLLED RELEASE; EMULSION-SOLVENT EVAPORATION METHOD; GLYCEMIA; IN-VITRO; IN-VIVO; MEAN PARTICLE SIZE; PANCREATIC HORMONES; PARTICULATE SYSTEMS; POLYDISPERSITY INDICES; POLYMERIC NANOPARTICLES; POLYMERIC PARTICLES; PROCESS YIELD; PROTEIN ENTRAPMENT; SMOOTH SURFACE; SUSTAINED RELEASE; THERAPEUTIC USE; WATER SOLUBILITIES;

DRUG PRODUCTS; EMULSIFICATION; MEDICAL PROBLEMS; NANOPARTICLES;

FUNCTIONAL POLYMERS;

AMYLIN; NANOPARTICLE; POLYCAPROLACTONE; POLYMER;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DISPERSION; DRUG FORMULATION; DRUG SCREENING; EMULSION; ENCAPSULATION; EVAPORATION; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; APPETITE DEPRESSANTS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; EMULSIONS; FASTING; HUMANS; INJECTIONS, SUBCUTANEOUS; ISLET AMYLOID POLYPEPTIDE; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; SOLUBILITY;

MUS;

EID: 84859159918     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.01.021     Document Type: Article

References (41)

1. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:8628-8632.
2. Cooper G.J., Willis A.C., Reid K.B., Clark A., Baker C.A., Turner R.C., Lewis C.E., Morris J.F., Howland K., Rothbard J.B. Diabetes-associated peptide. Lancet 1987, 2:966.
3. Westermark P., Wernstedt C., O'Brien T.D., Hayden D.W., Johnson K.H. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am. J Pathol. 1987, 127:414-417.
4. Westermark P., Wernstedt C., Wilander E., Hayden D.W., O'Brien T.D., Johnson K.H. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3881-3885.
5. Hayden M.R., Tyagi S.C. A is for amylin and amyloid in type 2 diabetes mellitus. J. Pancreas 2001, 2:124-139.
6. Young A. Amylin: Physiology and Pharmacology 2005, Elsevier Academic Press.
7. Cooper G.J.S. Amylin and related proteins: physiology and pathophysiology. Handbook of Physiology 2001, Oxford University Press, New York. L.S. Jefferson, Cherring (Eds.).
8. Broderick C.L., Brooke G.S., DiMarchi R.D., Gold G. Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets. Biochem. Biophys. Res. Commun. 1991, 177:932-938.
9. Bretherton-Watt D., Gilbey S.G., Ghatei M.A., Beacham J., Bloom S.R. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 1990, 33:115-117.
10. Ghatei M.A., Datta H.K., Zaidi M., Bretherton-Watt D., Wimalawansa S.J., MacIntyre I., Bloom S.R. Amylin and amylin-amide lack an acute effect on blood glucose and insulin. J. Endocrinol. 1990, 124:R9-R11.
11. Wilding J.P., Khandan-Nia N., Bennet W.M., Gilbey S.G., Beacham J., Ghatei M.A., Bloom S.R. Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994, 37:166-169.
12. Bretherton-Watt D., Gilbey S.G., Ghatei M.A., Beacham J., Macrae A.D., Bloom S.R. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J. Clin. Endocrinol. Metab. 1992, 74:1032-1035.
13. Young A. Clinical studies. Adv. Pharmacol. 2005, 52:289-320.
14. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:5036-5040.
15. Young A.A., Vine W., Gedulin B.R., Pittner R., Janes S., Gaeta L.S., Percy A., Moore C.X., Koda J.E., Rink T.J., Beaumont K. Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin. Drug Dev. Res. 1996, 37:231-248.
16. Ryan G., Briscoe T.A., Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des. Dev. Ther. 2009, 2:203-214.
17. Edelman S.V., Garg S., Kolterman O.G. Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:E1.
18. Pullman J., Darsow T., Frias J.P. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc. Health Risk Manag. 2006, 2:203-212.
19. Dunican K.C., Adams N.M., Desilets A.R. The role of pramlintide for weight loss. Ann. Pharmacother. 2010, 44:538-545.
20. Ioannides-Demos L.L., Piccenna L., McNeil J.J. Pharmacotherapies for obesity: past, current, and future therapies. J. Obes. 2011, 2011:179674.
21. Patil S.M., Xu S., Sheftic S.R., Alexandrescu A.T. Dynamic alpha-helix structure of micelle-bound human amylin. J. Biol. Chem. 2009, 284:11982-11991.
22. Nanga R.P., Brender J.R., Xu J., Hartman K., Subramanian V., Ramamoorthy A. Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy. J. Am. Chem. Soc. 2009, 131:8252-8261.
23. Singh G., Brovchenko I., Oleinikova A., Winter R. Peptide aggregation in finite systems. Biophys. J. 2008, 95:3208-3221.
24. Larson J.L., Miranker A.D. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol. 2004, 335:221-231.
25. Knight J.D., Williamson J.A., Miranker A.D. Interaction of membrane-bound islet amyloid polypeptide with soluble and crystalline insulin. Protein Sci. 2008, 17:1850-1856.
26. Wiltzius J.J., Sievers S.A., Sawaya M.R., Eisenberg D. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Sci. 2009, 18:1521-1530.
27. Yonemoto I.T., Kroon G.J., Dyson H.J., Balch W.E., Kelly J.W. Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry 2008, 47:9900-9910.
28. Cabaleiro-Lago C., Lynch I., Dawson K.A., Linse S. Inhibition of IAPP and IAPP(20-29) fibrillation by polymeric nanoparticles. Langmuir 2010, 26:3453-3461.
29. Blanco M.D., Alonso M.J. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur. J. Pharm. Biopharm. 1997, 43:287-294.
30. Perez C., Sanches A., Putnam D., Ting D., Langer R., Alonso M. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control. Release 2001, 75:211-224.
31. Udenfriend S., Stein S., Bohlen P., Dairman W., Leimgruber W., Weigele M. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science 1972, 178:871-872.
32. Pace C.N., Vajdos F., Fee L., Grimsley G., Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995, 4:2411-2423.
33. Jiao Y., Ubrich N., Marchand-Arvier M., Vigneron C., Hoffman M., Lecompte T., Maincent P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002, 105:203-205.
34. Panagiotidis G., Salehi A.A., Westermark P., Lundquist I. Homologous islet amyloid polypeptide: effects on plasma levels of glucagon, insulin and glucose in the mouse. Diabetes Res. Clin. Pract. 1992, 18:167-171.
35. Finotelli P.V., Da S.D., Sola-Penna M., Rossi A.M., Farina M., Andrade L.R., Takeuchi A.Y., Rocha-Leao M.H. Microcapsules of alginate/chitosan containing magnetic nanoparticles for controlled release of insulin. Colloids Surf. B Biointerfaces 2010, 81:206-211.
36. L.H. Guerreiro, D. Da Silva, M. Sola-Penna, D.M. Mizurini, L.M.T.R. Lima, 2012. unpublished work.
37. Ayala J.E., Samuel V.T., Morton G.J., Obici S., Croniger C.M., Shulman G.I., Wasserman D.H., McGuinness O.P. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis. Model. Mech. 2010, 3:525-534.
38. Wagner J.G. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J. Pharm. Sci. 1969, 58:1253.
39. Sheriff S., Fischer J.E., Balasubramaniam A. Amylin inhibits insulin-stimulated glucose uptake in C2C12 muscle cell line through a cholera-toxin-sensitive mechanism. Biochim. Biophys. Acta 1992, 1136:219-222.
40. Horcajada-Molteni M.N., Chanteranne B., Lebecque P., Davicco M.J., Coxam V., Young A., Barlet J.P. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J. Bone Miner. Res. 2001, 16:958-965.
41. Kim S.Y., Lee Y.M., Baik D.J., Kang J.S. Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres: in vitro and in vivo studies in the normal mice. Biomaterials 2003, 24:55-63.